Calidi Biotherapeutics (CLDI) Cash from Financing Activities (2022 - 2025)

Calidi Biotherapeutics has reported Cash from Financing Activities for 4 years, with the latest figure at $340000.0 in Q4 2025.

• For the quarter ending Q4 2025, Cash from Financing Activities fell 97.41% year-over-year to $340000.0; the trailing twelve-month figure through Dec 2025 stood at $17.5 million (down 36.2% YoY), and the FY2025 full-year result was $17.5 million, down 36.2% from the prior year.
• Cash from Financing Activities for Q4 2025 stood at $340000.0, down from $9.5 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $21.6 million in Q3 2023, with the low at -$3.0 million in Q4 2023.
• Average Cash from Financing Activities over 4 years is $6.1 million, with a median of $5.6 million recorded in 2024.
• Year-over-year, Cash from Financing Activities slumped 168.49% in 2023 and soared 543.07% in 2024.
• Tracing CLDI's Cash from Financing Activities over 4 years: stood at $4.3 million in 2022, then slumped by 168.49% to -$3.0 million in 2023, then soared by 543.07% to $13.1 million in 2024, then sank by 97.41% to $340000.0 in 2025.
• The last three Cash from Financing Activities figures came in at $340000.0 (Q4 2025), $9.5 million (Q3 2025), and -$469000.0 (Q2 2025), per Business Quant data.

Peer Comparison